DOCSLIB.ORG

LPO' Enforcement in 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Voluntary Report – Voluntary - Public Distribution Date: April 30, 2021 Report Number: MX2021-0023 Report Name: Mexico Organic Law 'LPO' Enforcement in 2021 Country: Mexico Post: Mexico City Report Category: Special Certification - Organic/Kosher/Halal Prepared By: USDA Approved By: Daniel Alvarado Report Highlights: On December 26, 2020, Mexico published a measure that requires most organic raw materials and bulk products to be certified to Mexico’s Organic Law (LPO) standards by June 26, 2021. The Measure includes an annex that lists the products which will require proof of LPO certification at the border. While USDA has requested an extension of the June 26, 2021 deadline, Mexico has not approved an extension and U.S. stakeholders should prepare for compliance on June 26, 2021. Mexico’s organics regulator, the National Service for Animal and Plant Health, Food Safety and Quality (SENASICA), is fully responsible for certifying and enforcing the LPO requirements. This report contains a summary of SENASICA’s public statements on this Measure and contact information for parties seeking additional information. THIS REPORT CONTAINS ASSESSMENTS OF COMMODITY AND TRADE ISSUES MADE BY USDA STAFF AND NOT NECESSARILY STATEMENTS OF OFFICIAL U.S. GOVERNMENT POLICY Executive Summary: On December 26, 2020, Mexico published a measure (the Measure) stating products which will be marketed as organic in Mexico will need to show compliance at the border with Mexico’s organic law (LPO). The Measure includes an annex listing the scope of products (by HS code) that must be certified. A summary of this list is included in the pages of this report. The deadline for enforcement of this Measure is June 26, 2021. Because Mexico does not currently recognize USDA organic certification, U.S. organic products exported to Mexico must be certified to the LPO. In order to be certified to the LPO, U.S. operators must be certified by a SENASICA-accredited certifying body. There are currently 12 certifying bodies accredited by SENASICA that are also accredited by the NOP. Product already certified to the USDA’s organic standards may be “recertified” to the LPO by a SENASICA-accredited certifying body. SENASICA has listed two methods to contact its staff with questions about implementation of the Measure: 1) email to [email protected], or 2) telephone to (+52) 55 5905 1000, ext. 51509, 51523, or 51532. For presentations and other resources from SENASICA’s April 12, 2021 webinar, please see SENASICA’s website. Disclaimer: SENASICA is solely responsible for the implementation of the Measure and the LPO. USDA is providing this GAIN report only as a summary of public information provided by SENASICA. All questions regarding the LPO should be directed to SENASICA using the contacts listed above. Page 2 of 41 Background: Mexico published its original national organic law and corresponding standards in 2006 under the Ley de Productos Orgánicos (LPO). See GAIN Report No. MX6501. In 2015, Mexico published allowance of a grace period (from May 2015–October 2016; see GAIN report no. MX2015-2073) for which organic exports to Mexico should come into compliance with the LPO and its regulatory updates in 2010 and guidelines on labeling and production in 2013. On June 8, 2020, the Government of Mexico (GOM) published the Modifications to the Guidelines for the Organic Operations in its federal gazette, finalizing a multi-year process of revising the LPO’s organic standards. Official GOM information about the guidelines can be found here. Although the LPO requires organic products imported to Mexico to be certified to the LPO standards, or an equivalent standard, Mexico agreed to not enforce these requirements while it was conducting equivalence discussions. As a result, U.S. organic exports to Mexico are certified to the NOP standard and have been shipped to Mexico where they could be legally marketed as organic and bear the USDA organic seal. The December 2020 Measure: On December 17, 2020, Mexico hosted a webinar with industry stakeholders and informed that SENASICA would begin enforcing the LPO requirements on December 28, 2020. Prior to this, in November 2020, Mexico published a draft measure on the Regulatory Improvement Commission’s (CONAMER) site titled, “Acuerdo que Establece las Mercancías Cuya Importación y Exportación está Sujeta a Regulación por Parte de la Secretaría de Agricultura y Desarrollo Rural” (“Agreement Establishing Goods whose Import and Export are Subject to Regulation by the Ministry of Agriculture and Rural Development”). See GAIN Report No. MX2020-0078. In Article 7 of the Measure, Mexico stated: In accordance with the provisions of articles 33 and 35 of the Organic Products Law, and 45 of its Regulations, the importer must present to the DGIF staff, at the point of entry into the country, the current Organic Certificate that protects the organic quality of each of the goods to be imported, as well as the Control Document, issued by an organic certification body approved by SENASICA or by an organic certification body under the control system of a country with which Mexico is equivalent in terms of organic products. This draft measure also included an annex and listed the products in tables b) – f) that would need to prove compliance under the LPO at the border (the Annex). This initial draft version gave a compliance deadline of December 28, 2020 (the date the measure would become final). Mexico revised the draft Measure and published the final version on December 26, 2020 in the Diario Oficial, to include a transitory Article Four, extending the compliance deadline to 180 Page 3 of 41 days from the date the Measure entered into force (June 26, 2021). The measure entered into force on December 28, 2020, per the Diario Oficial. Mexico notified this draft measure to the World Trade Organization (WTO) Sanitary and Phytosanitary (SPS) Committee on December 21, 2020 as SPS/N/MEX/230/Add.3. On January 4, 2021, the United States submitted an Enquiry Point request to Mexico to notify the Measure to the Technical Barriers to Trade (TBT) Committee; the re-notification is pending.1 Compliance Deadline: Initially, Mexico planned for the Measure to be fully enforced on December 28, 2020. Mexico delayed the compliance deadline for 180 days until June 26, 2021. Due to the number of changes that organic industry stakeholders in both Mexico and the United States must make in order to fully comply with the LPO standards, USDA has asked for an extension until at least December 31, 2021. Until there is a written, public notice stating otherwise, U.S. stakeholders should prepare for compliance to the LPO standards on June 26, 2021. See GAIN No. MX2020-0079. Scope: Raw Material / Ingredients Annex b) – f) of the Measure lists the tariff codes for all products subject to compliance with Mexico’s phytosanitary, zoo sanitary, and aquaculture health requirements. According to SENASICA, for the products in Annex b) – f) to be listed as “organic” at the point of entry, they must be accompanied by an organic certificate demonstrating certification to the LPO and a transaction certificate issued by a certifying agent approved by SENASICA. However, SENASICA states in its written responses to the April 12 seminar (Question 25) that only organic products that will be marketed in Mexico as organic need to be certified to the LPO. If raw materials are exported to Mexico as USDA organic, then processed in Mexico—but not marketed in Mexico—and re-imported to the United States or another country to be sold as USDA organic, those products do not need to be certified to the LPO. For the most part, the products listed in the Annex b) – f) by 8-digit HS code are raw ingredients or bulk materials. In Annex b) – f), there are several listings for “others.” SENASICA has stated that the intent in these cases is to include all other products that are similar to the ones specifically named but which do not have their own tariff code due to a small trading volume. A summary list is included in the pages of this report; however, the summary list is for convenience only and affected parties should refer to the full list. The full list is included as a courtesy, unofficial, professional translation here, as an attachment to this report. 1 Organic standards do not address risks to plant, animal or human health, nor do they support health claims of any kind. WTO Members maintain separate and distinct regulations for determining whether a food is safe to consume, and for addressing plant and animal health. Organic programs, therefore, fall under the scope of the TBT Agreement. Page 4 of 41 Processed Products / Retail SENASICA has also informed stakeholders in presentations and via written responses (find courtesy, unofficial English translation attached to this GAIN report) that an existing memorandum of understanding (MOU) between SENASICA and the Federal Consumer Protection Office (PROFECO) will expand the scope of LPO enforcement to all organic products marketed in Mexico, to include processed products at the retail level. Mexican Outreach and Resources: SENASICA first informed industry about the upcoming changes during a webinar on December 17, 2020. SENASICA also gave a webinar to U.S. industry and stakeholders on April 12, 2021. Mexico requested questions regarding the LPO be sent to [email protected], or by contacting SENASICA staff at +52 55 5905 1000, ext. 51509, 51523, and 51532. Certification and Accreditation: SENASICA stated that the following types of operations must be certified to the LPO: 1. Plant production 2. Plant production (wild collection) 3. Animal production (domestic) 4. Animal production of natural ecosystems or non-domestic 5. Animal production (insects) 6. Production of fungi 7.
Recommended publications
  • Stable Isotope-Labeled Productsfor Metabolic Research

    Stable Isotope-Labeled Productsfor Metabolic Research

    RESEARCH PRODUCTS Cambridge Isotope Laboratories, Inc. isotope.com Stable Isotope-Labeled Products For Metabolic Research Cambridge Isotope Laboratories, Inc. North America: 1.800.322.1174 [email protected] | International: +1.978.749.8000 [email protected] | fax: 1.978.749.2768 | isotope.com Cambridge Isotope Laboratories, Inc. | Stable Isotope-Labeled Products for Metabolic Research Stable Isotopes in Metabolomics and Metabolism Gary J. Patti Department of Chemistry, Washington University, St. Louis, Missouri 63130 United States Recent advances in mass spectrometry (MS) and nuclear comparing two sample groups, for example, an elevated magnetic resonance (NMR) technologies have greatly metabolite level may indicate increased or decreased enhanced metabolite analysis. Hundreds to thousands pathway flux. This is because metabolites can accumulate of metabolites can now be measured simultaneously with not only due to increased production, but also due to unprecedented accuracy from exceedingly small amounts decreased consumption. Yet, the difference between of biological material. These technical developments have increased production and decreased consumption may yield given rise to the field of metabolomics, which generally entirely different experimental interpretations. In a biomedical aims to assess metabolic regulation as a function of health context, for instance, increased production of a metabolite and disease. During the last decade, it has become relatively may suggest pharmacological inhibition of the pathway as a routine to perform metabolomic analysis on most biological therapeutic strategy. Thus, to understand pathway regulation samples. Interpretation of the acquired data, however, and metabolic mechanisms of disease, the application of remains a considerable challenge. Stable isotopes are isotopic tracers is required. providing experimental strategies that overcome some of these barriers.
  • Catalog Stable Isotope-Labeled Products for Metabolic Research

    Catalog Stable Isotope-Labeled Products for Metabolic Research

    Cambridge Isotope Laboratories, Inc. isotope.com Stable Isotope-Labeled Products For Metabolic Research Euriso-Top, Parc des Algorithmes, route de l'orme, 91190 Saint Aubin | France tel: +33 1 69 41 97 98 fax: +33 1 69 41 93 52 +49 (0) 681 99 63 338 (Germany) www.eurisotop.com Cambridge Isotope Laboratories, Inc. | Stable Isotope-Labeled Products for Metabolic Research Stable Isotopes in Metabolomics and Metabolism Gary J. Patti Department of Chemistry, Washington University, St. Louis, Missouri 63130 United States Recent advances in mass spectrometry (MS) and nuclear comparing two sample groups, for example, an elevated magnetic resonance (NMR) technologies have greatly metabolite level may indicate increased or decreased enhanced metabolite analysis. Hundreds to thousands pathway flux. This is because metabolites can accumulate of metabolites can now be measured simultaneously with not only due to increased production, but also due to unprecedented accuracy from exceedingly small amounts decreased consumption. Yet, the difference between of biological material. These technical developments have increased production and decreased consumption may yield given rise to the field of metabolomics, which generally entirely different experimental interpretations. In a biomedical aims to assess metabolic regulation as a function of health context, for instance, increased production of a metabolite and disease. During the last decade, it has become relatively may suggest pharmacological inhibition of the pathway as a routine to perform metabolomic analysis on most biological therapeutic strategy. Thus, to understand pathway regulation samples. Interpretation of the acquired data, however, and metabolic mechanisms of disease, the application of remains a considerable challenge. Stable isotopes are isotopic tracers is required.
  • Campro Catalog Stable Isotope

    Campro Catalog Stable Isotope

    Introduction & Welcome Dear Valued Customer, We are pleased to present to you our Stable Isotopes Catalog which contains more than three thousand (3000) high quality labeled compounds. You will find new additions that are beneficial for your research. Campro Scientific is proud to work together with Isotec, Inc. for the distribution and marketing of their stable isotopes. We have been working with Isotec for more than twenty years and know that their products meet the highest standard. Campro Scientific was founded in 1981 and we provide services to some of the most prestigious universities, research institutes and laboratories throughout Europe. We are a research-oriented company specialized in supporting the requirements of the scientific community. We are the exclusive distributor of some of the world’s leading producers of research chemicals, radioisotopes, stable isotopes and environmental standards. We understand the requirements of our customers, and work every day to fulfill them. In working with us you are guaranteed to receive: - Excellent customer service - High quality products - Dependable service - Efficient distribution The highly educated staff at Campro’s headquarters and sales office is ready to assist you with your questions and product requirements. Feel free to call us at any time. Sincerely, Dr. Ahmad Rajabi General Manager 180/280 = unlabeled 185/285 = 15N labeled 181/281 = double labeled (13C+15N, 13C+D, 15N+18O etc.) 186/286 = 12C labeled 182/282 = d labeled 187/287 = 17O labeled 183/283 = 13C labeleld 188/288 = 18O labeled 184/284 = 16O labeled, 14N labeled 189/289 = Noble Gases Table of Contents Ordering Information.................................................................................................. page 4 - 5 Packaging Information ..............................................................................................
  • Download Product Insert (PDF)

    Download Product Insert (PDF)

    Product Information Boldenone Cypionate Item No. 15158 CAS Registry No.: 106505-90-2 O Formal Name: 17β-hydroxy-androsta-1,4-dien-3-one O cyclopentanepropionate MF: C27H38O3 FW: 410.6 H Purity: ≥95% Stability: ≥2 years at -20°C H H Supplied as: A crystalline solid λ O UV/Vis.: max: 244 nm Laboratory Procedures For long term storage, we suggest that boldenone cypionate be stored as supplied at -20°C. It should be stable for at least two years. Boldenone cypionate is supplied as a crystalline solid. A stock solution may be made by dissolving the boldenone cypionate in the solvent of choice. Boldenone cypionate is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of boldenone cypionate in these solvents is approximately 15, 5, and 25 mg/ml, respectively. Boldenone cypionate is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, boldenone cypionate should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. Boldenone cypionate has a solubility of approximately 0.3 mg/ml in a 1:2 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. Boldenone is an anabolic androgenic steroid and synthetic derivative of testosterone that was originally developed for veterinary use.1 It can increase nitrogen retention, protein synthesis, and appetite, and also stimulates the release of erythropoietin in the kidneys.1 Boldenone cypionate was synthesized as an ester of boldenone in an attempt to alter boldenone’s very long half-life.2 Anabolic androgenic steroid compounds such as boldenone cypionate have been used illicitly by bodybuilders and other athletes.3 This compound is intended for forensic and research purposes only.
  • Abigail Marklew, Juha Kammonen, Emma Richardson & Jonathan

    Abigail Marklew, Juha Kammonen, Emma Richardson & Jonathan

    Development and validation of NMDA receptor ligand- gated ion channel assays using the Qube 384 automated electrophysiology platform Abigail Marklew, Juha Kammonen, Emma Richardson & Jonathan Mann Saffron Walden, Essex, UK Abigail Marklew, Juha Kammonen, Emma Richardson and Gary Clark Saffron1 ABSTRACT Walden, Essex, UK 2 MATERIALS AND METHODS Ligand-gated ion channels are of particular interest to the pharmaceutical industry for the Cell Culture: HEK-NMDA NR1/N2A receptor cells were produced at Charles River Laboratories and treatment of diseases from a variety of therapeutic areas including CNS disorders, respiratory are commercially available. All cells were grown according to their respective SOPs as developed by disease and chronic pain. Ligand-gated ion channels have historically been investigated using Charles River, except for the use of D-(-)-AP-5 as antagonist during induction. Cells were kept in a fluorescence-based and low throughput patch-clamp techniques. However the development of the serum-free medium in the cell hotel on the Qube instrument for up to 4 hours during experiment. Qube 384 automated patch-clamp system has allowed rapid exchange of liquid and direct Induction: Cells were induced 24 h prior to use using 1 µg/mL tetracycline and 100 µM D-(-)-AP-5 in measurement of ion channel currents on a millisecond timescale, making it possible to run HTS neurobasal medium + 10% dialysed FBS. campaigns and support SAR with a functional readout. Solutions: The following extracellular saline solution was used (mM): 145 NaCl. 4 KCl, 10 HEPES, 10 Glucose, 2 CaCl2, pH7.4. Intracellular solution (mM): 70 KCl, 70 KF, 10 HEPES, 1 EGTA, pH7.2.
  • Ranvet's Filybol

    Ranvet's Filybol

    Ranvet's Filybol Ranvet Chemwatch Hazard Alert Code: 2 Chemwatch: 4787-83 Issue Date: 08/02/2016 Version No: 5.1.1.1 Print Date: 10/28/2016 Safety Data Sheet according to WHS and ADG requirements S.GHS.AUS.EN SECTION 1 IDENTIFICATION OF THE SUBSTANCE / MIXTURE AND OF THE COMPANY / UNDERTAKING Product Identifier Product name Ranvet's Filybol Chemical Name peanut oil Synonyms Not Available Other means of Not Available identification Relevant identified uses of the substance or mixture and uses advised against Relevant identified Non-virilising anabolic combination for fillies, mares, colts and stallions. uses Details of the supplier of the safety data sheet Registered company Ranvet name Address 10-12 Green Street Banksmeadow NSW 2019 Australia Telephone +61 2 9666 1744 Fax +61 2 9666 1755 Website https://www.ranvet.com.au/other_msds.htm Email [email protected] Emergency telephone number Association / Not Available Organisation Emergency telephone +61 425 061 584 numbers Other emergency Not Available telephone numbers SECTION 2 HAZARDS IDENTIFICATION Classification of the substance or mixture Poisons Schedule S4 Carcinogenicity Category 2, Reproductive Toxicity Category 2, Acute Aquatic Hazard Category 2, Chronic Aquatic Hazard Classification [1] Category 2 1. Classified by Chemwatch; 2. Classification drawn from HSIS ; 3. Classification drawn from EC Directive 1272/2008 - Annex Legend: VI Label elements GHS label elements SIGNAL WORD WARNING Continued... Chemwatch: 4787-83 Page 2 of 10 Issue Date: 08/02/2016 Version No: 5.1.1.1 Ranvet's Filybol Print Date: 10/28/2016 Hazard statement(s) H351 Suspected of causing cancer. H361 Suspected of damaging fertility or the unborn child.
  • Download (PDF 277.63

    Download (PDF 277.63

    PROJECT REVIEW “Characterization of the main metabolites of 17-methylstenblone and 17 methylmethenolone produced by human hepatocytes and liver fractions” Prof C. Ayotte, (INRS-Institut Armand-Frappier, Canada) New steroids openly appear on the market in products labelled with a rather confusing nomenclature. Once characterized, pharmaceutical grade products not being available, knowledge of the biotransformation pathways essential to an efficient detection of utilization by athletes is difficult to gain since administration to human volunteers should be restricted to the minimum. The alternative is a reliable in vitro model. Human hepatocytes, fresh or cryopreserved are now available commercially. We have successfully produced and identified phase I metabolites from incubations of human hepatocytes with different steroids, such as 17-methyldrostanolone and desoxymethyltestosterone (DMT). The aim of this project is to produce in vitro from human hepatocytes and liver fractions the metabolites of two steroids, the 17-methylated derivatives of stenbolone and its isomer methenolone. The principal metabolites will be synthesized and characterized by NMR and mass spectrometry. The characterization of metabolites will enable the identification of markers of utilization to be incorporated in routine testing methods. The approach for the chemical synthesis of metabolites will be shared with NMI insuring the distribution to other doping control laboratories. Improving the knowledge of steroid biotransformation is a further benefit from these studies. Characterization of 17-Methylstenbolone and 17-Methylmethenolone and Identification of Metabolites Produced by Human Hepatocytes and Liver Fractions WADA Project no. 11A16CA Christiane Ayotte, Philippe Räss, Alexandre Sylvestre, INRS-Institut Armand-Frappier Summary We have synthesized and characterized two designer steroids, 17α-methylmethenolone and 17α- methylstenbolone; the latter is proposed on the internet and two groups have reported different and contradictory results.
  • Investigation Into Potential Endocrine Disruptive Effects of Sceletium Tortuosum

    Investigation Into Potential Endocrine Disruptive Effects of Sceletium Tortuosum

    Investigation into potential endocrine disruptive effects of Sceletium tortuosum by Letitia Louw Dissertation presented for the degree of Master of Science in the Faculty of Science at Stellenbosch University Supervisor: Prof C. Smith Co-supervisor: Prof AC. Swart March 2018 Stellenbosch University https://scholar.sun.ac.za Declaration By submitting this dissertation electronically, I declare that the entirety of the work contained therein is my own, original work, that I am the sole author thereof (save to the extent explicitly otherwise stated), that reproduction and publication thereof by Stellenbosch University will not infringe any third party rights and that I have not previously in its entirety or in part submitted it for obtaining any qualification. March 2018 Copyright © 2018 Stellenbosch University All rights reserved i Stellenbosch University https://scholar.sun.ac.za What if I fall? Oh, but darling what if you fly? ii Stellenbosch University https://scholar.sun.ac.za ABSTRACT Depression has been recognised by the World Health Organisation (WHO) as the leading cause of disability, affecting an estimated 300 million people globally. To date antidepressants are prescribed as the first step in the treatment strategy. However, finding the appropriate antidepressant is often a lengthy process and is usually accompanied by side effects. A major and often unexpected side effect is reduced sexual function, which has been reported to aggravate depression and could possibly lead to poor compliance to medication. Sceletium tortuosum is a native South African plant, which has exhibited both antidepressant and anxiolytic properties. Although the exact mechanism of action remains to be elucidated, there are currently two hypotheses which attempt to explain it’s mechanism of action.
  • Us Anti-Doping Agency

    Us Anti-Doping Agency

    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
  • (12) United States Patent (10) Patent No.: US 9,642,912 B2 Kisak Et Al

    (12) United States Patent (10) Patent No.: US 9,642,912 B2 Kisak Et Al

    USOO9642912B2 (12) United States Patent (10) Patent No.: US 9,642,912 B2 Kisak et al. (45) Date of Patent: *May 9, 2017 (54) TOPICAL FORMULATIONS FOR TREATING (58) Field of Classification Search SKIN CONDITIONS CPC ...................................................... A61K 31f S7 (71) Applicant: Crescita Therapeutics Inc., USPC .......................................................... 514/171 Mississauga (CA) See application file for complete search history. (72) Inventors: Edward T. Kisak, San Diego, CA (56) References Cited (US); John M. Newsam, La Jolla, CA (US); Dominic King-Smith, San Diego, U.S. PATENT DOCUMENTS CA (US); Pankaj Karande, Troy, NY (US); Samir Mitragotri, Santa Barbara, 5,602,183 A 2f1997 Martin et al. CA (US); Wade A. Hull, Kaysville, UT 5,648,380 A 7, 1997 Martin 5,874.479 A 2, 1999 Martin (US); Ngoc Truc-ChiVo, Longueuil 6,328,979 B1 12/2001 Yamashita et al. (CA) 7,001,592 B1 2/2006 Traynor et al. 7,795,309 B2 9/2010 Kisak et al. (73) Assignee: Crescita Therapeutics Inc., 8,343,962 B2 1/2013 Kisak et al. Mississauga (CA) 8,513,304 B2 8, 2013 Kisak et al. 8,535,692 B2 9/2013 Pongpeerapat et al. (*) Notice: Subject to any disclaimer, the term of this 9,308,181 B2* 4/2016 Kisak ..................... A61K 47/12 patent is extended or adjusted under 35 2002fOOO6435 A1 1/2002 Samuels et al. 2002fOO64524 A1 5, 2002 Cevc U.S.C. 154(b) by 204 days. 2005, OO 14823 A1 1/2005 Soderlund et al. This patent is Subject to a terminal dis 2005.00754O7 A1 4/2005 Tamarkin et al.
  • Androgenic-Anabolic Steroid (Boldenone)

    Androgenic-Anabolic Steroid (Boldenone)

    Genera of l P l r a a n c r t u i c o e J Kalmanovich et al., J Gen Pract 2014, 2:3 Journal of General Practice DOI: 10.4172/2329-9126.1000153 ISSN: 2329-9126 Case Report Open Access Androgenic-Anabolic Steroid (Boldenone) Abuse as a Cause of Dilated Cardiomyopathy Eran Kalmanovich*, Sa'ar Minha, Marina Leitman, Zvi Vered and Alex Blatt Assaf Harofeh Medical Center, Aviv University, Israel *Corresponding author: Eran Kalmanovich, Department of Cardiology, Assaf Harofeh Medical Center, Zerifin, Sackler School of Medicine, Tel Aviv University, Israel, Tel: +972-50-5191121; E-mail: [email protected] Received date: Feb 27, 2014, Accepted date: Mar 27, 2014, Published date: Apr 3, 2014 Copyright: © 2014 Kalmanovich E, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Case Presentation At admission 1-year follow up A 34-year old, previously healthy male, presented to the ER with EF% 20% 40% worsening dyspnea over a period of three weeks and the appearance of blood tinged sputum. Soon after presentation, the patient was LA diameter (mm) 3.9 3.8 hypoxemic and required mechanical ventilation. Chest X-ray LA area (cm2) 14.0 20 demonstrated bilateral infiltrates and he was admitted to the ICU with the tentative diagnosis of acute respiratory distress syndrome. LVEDD (cm) 6.1 5.6 Investigation by PICCO, Suggested the presence of heart failure were LVESD (cm) 5.1 3.3 and the patient was transferred to the ICCU.
  • WO 2018/190970 Al 18 October 2018 (18.10.2018) W !P O PCT

    WO 2018/190970 Al 18 October 2018 (18.10.2018) W !P O PCT

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/190970 Al 18 October 2018 (18.10.2018) W !P O PCT (51) International Patent Classification: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, CI2Q 1/32 (2006.01) UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (21) International Application Number: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, PCT/US2018/021 109 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (22) International Filing Date: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 06 March 2018 (06.03.2018) KM, ML, MR, NE, SN, TD, TG). (25) Filing Language: English Declarations under Rule 4.17: (26) Publication Langi English — as to applicant's entitlement to apply for and be granted a patent (Rule 4.1 7(H)) (30) Priority Data: — as to the applicant's entitlement to claim the priority of the 62/484,141 11 April 2017 ( 11.04.2017) US earlier application (Rule 4.17(Hi)) (71) Applicant: REGENERON PHARMACEUTICALS, Published: INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown, — with international search report (Art. 21(3)) New York 10591-6707 (US). — with sequence listing part of description (Rule 5.2(a)) (72) Inventors: STEVIS, Panayiotis; 777 Old Saw Mill Riv er Road, Tarrytown, New York 10591-6707 (US).